EGFR heterogeneity and implications for therapeutic intervention in glioblastoma

Eskil Eskilsson, Gro V. Røsland, Gergely Solecki, Qianghu Wang, Patrick N. Harter, Grazia Graziani, Roel G.W. Verhaak, Frank Winkler, Rolf Bjerkvig, Hrvoje Miletic*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

176 Citations (Scopus)


Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need of effective treatment strategies. Recent advances in sequencing techniques unraveled the complete genomic landscape of GBMs and revealed profound heterogeneity of individual tumors even at the single cell level. Genomic profiling has detected epidermal growth factor receptor (EGFR) gene alterations in more than half of GBMs. Major genetic events include amplification and mutation of EGFR. Yet, treatment strategies targeting EGFR have thus far failed in clinical trials. In this review, we discuss the clonal and functional heterogeneity of EGFRs in GBM development and critically reassess the potential of EGFRs as therapeutic targets.

Original languageEnglish
Pages (from-to)743-752
Number of pages10
Issue number6
Publication statusPublished - 18 May 2018


  • EGFR
  • angiogenesis
  • glioblastoma
  • invasion
  • targeted therapy
  • tumor heterogeneity


Dive into the research topics of 'EGFR heterogeneity and implications for therapeutic intervention in glioblastoma'. Together they form a unique fingerprint.

Cite this